MBX Biosciences, Inc. Common Stock MBX · Stock Open MBX Biosciences, Inc. Common Stock in new tab
MBX Biosciences, Inc. Common Stock Analysis (MBX)
Is MBX Biosciences, Inc. Common Stock a good investment? MBX Biosciences, Inc. Common Stock (MBX) is currently trading at 64.41 USD. Market analysts have a consensus price target of 77.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: MBX Biosciences, Inc. Common Stock is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -3.60.
Investor FAQ
Does MBX Biosciences, Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is MBX Biosciences, Inc. Common Stock?
MBX Biosciences, Inc. Common Stock is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -2.17.
Company Profile
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Community Discussion